Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer

Cancer Investigation

Volumn 28, Issue 8, 2010, Pages 828-832

  Erfani, Nasrollah ^a   Razmkhah, Mahbobeh ^a   Ghaderi, Abbas ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast; Cancer; Circulating sCTLA4; Immune suppression; Soluble CTLA4

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; SOLUBLE CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR IMMUNITY; BLOOD; BREAST TUMOR; FEMALE; GENETICS; GENOTYPE; PAGET NIPPLE DISEASE; PATIENT SELECTION; PROCEDURES; REFERENCE VALUE;

ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA, DUCTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL; CTLA-4 ANTIGEN;

EID: 77956637830     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003630934     Document Type: Article

References (37)

1. Oaks, M.K.; Hallett, K.M.; Penwell, R.T.; Stauber, E.C.; Warren, S.J.; Tector, A.J. A native soluble form of CTLA-4. Cell Immunol 2000, 201(2), 144-153.
2. Pioli, C.; Gatta, L.; Ubaldi, V.; Doria, G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J Immunol 2000, 165(10), 5530-5536.
3. Magistrelli, G.; Jeannin, P.; Herbault, N.; Benoit De, C.A., Gauchat, J.F.; Bonnefoy, J.Y.; Delneste, Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999, 29(11), 3596-3602.
4. Oaks, M.K.; Hallett, K.M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000, 164(10), 5015-5018.
5. Tarhini, A.A.; Kirkwood, J.M. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther 2007, 9(5), 505-514.
6. Liu, M.F.;Wang, C.R.; Chen, P.C.; Fung, L.L. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 2003, 57(6), 568-572.
7. Wang, X.B.; Kakoulidou, M.; Giscombe, R.; Qiu, Q.; Huang, D.; Pirskanen, R.; Lefvert, A.K. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002, 130(1-2), 224-232.
8. Sato, S.; Fujimoto, M.; Hasegawa, M.; Komura, K.; Yanaba, K.; Hayakawa, I.; Matsushita, T.; Takehara, K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004, 43(10), 1261-1266.
9. Piras, G.;Monne, M.; Uras, A.; Palmas, A.;Murineddu, M.; Arru, L.; Bianchi, A.; Calvisi, A.; Curreli, L.; Gaviano, E.; Lai, P.; Murgia, A.; Latte, G.C.; Noli, A.; Gabbas, A. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkins lymphoma. Br J Haematol 2005, 129(6), 784-790.
10. Ghaderi, A.; Yeganeh, F.; Kalantari, T.; Talei, A.R.; Pezeshki, A.M.; Doroudchi, M.; Dehaghani, A.S. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004, 86(1), 1-7.
11. Cozar, J.M.; Romero, J.M.; Aptsiauri, N.; Vazquez, F.; Vilchez, J.R.; Tallada, M.; Garrido, F.; Ruiz-Cabello, F. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007, 68(8), 698-704.
12. Wang, L.; Li, D.; Fu, Z.; Li, H.; Jiang, W.; Li, D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007, 7, 173.
13. Galea, M.H.; Blamey, R.W.; Elston, C.E.; Ellis, I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22(3), 207-219.
14. Fernandez-Blanco, L; Perez-Pampin, E.; Gomez-Reino, J.J.; Gonzalez, A. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum 2004, 50(1), 328-329.
15. Hudson, L.L.; Rocca, K.; Song, Y.W.; Pandey, J.P. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 2002, 111(4-5), 452-455.
16. Donner, H.; Braun, J.; Seidl, C.; Rau, H.; Finke, R.; Ventz, M.; Walfish, P.G.; Usadel, K.H.; Badenhoop, K. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimotos thyroiditis and Addisons disease. J Clin Endocrinol Metab 1997, 82(12), 4130-4132.
17. Marron, M.P.; Zeidler, A.; Raffel, L.J.; Eckenrode, S.E.; Yang, J.J.; Hopkins, D.I.; Garchon, H.J.; Jacob, C.O.; Serrano-Rios, M.; Martinez Larrad, M.T.; Park, Y.; Bach, J.F.; Rotter, J.I.; Yang, M.C.; She, J.X. Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. Diabetes 2000, 49(3), 492-499.
18. Torres, B.; Aguilar, F.; Franco, E.; Sanchez, E.; Sanchez-Roman, J.; Jimenez, A.J.; Nunez-Roldan, A.; Martin, J.; Gonzalez-Escribano, M.F. Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis Rheum 2004, 50(7), 2211-2215.
19. Hadj, K.H.; Bellassoued, M.; Bougacha-Elleuch, N.; Abid, M.; Ayadi, H. CTLA-4 gene polymorphisms in Tunisian patients with Graves disease. Clin Immunol 2001, 101(3), 361-365.
20. Purohit, S.; Podolsky, R.; Collins, C.; Zheng, W.; Schatz, D.; Muir, A.; Hopkins, D.; Huang, Y.H.; She, J.X. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2005, 2, 8.
21. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M.L.; Bianchi, R.; Fioretti, M.C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3(11), 1097-1101.
22. Masteller, E.L.; Chuang, E.; Mullen, A.C.; Reiner, S.L.; Thompson, C.B. Structural analysis of CTLA-4 function in vivo. J Immunol 2000, 164(10), 5319-5327.
23. Huurman, V.A.; Unger, W.W.; Koeleman, B.P.; Oaks, M.K.; Chandraker, A.K.; Terpstra, O.T.; Roep, B.O. Differential inhibition of autoreactive memory-and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 2007, 150(3), 487-493.
24. Orabona, C.; Belladonna, M.L.; Vacca, C.; Bianchi, R.; Fallarino, F.; Volpi, C.; Gizzi, S.; Fioretti, M.C.; Grohmann, U.; Puccetti, P. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005, 174(11), 6582-6586.
25. Caras, I.; Grigorescu, A.; Stavaru, C.; Radu, D.L.;Mogos, I.; Szegli, G.; Salageanu, A. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004, 53(12), 1146-1152.
26. Di, G. V.; Laguens, R.P.; Coronato, S.; Salas, M.; Spinelli, O.; Portiansky, E.; Laguens, G. Quantitative and functional study of breast cancer axillary lymph nodes and those draining other human malignant tumors. J Exp Clin Cancer Res 2000, 19(2), 155-159.
27. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Snook, H.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.; Smith, A.N.; Di Genova, G.; Herr, M.H.; Dahlman, I.; Payne, F.; Smyth, D.; Lowe, C.; Twells, R.C.; Howlett, S.; Healy, B.; Nutland, S.; Rance, H.E.; Everett, V.; Smink, L.J.; Lam, A.C.; Cordell, H.J.; Walker, N.M.; Bordin, C.; Hulme, J.; Motzo, C.; Cucca, F.; Hess, J.F.; Metzker, M.L.; Rogers, J.; Gregory, S.; Allahabadia, A.; Nithiyananthan, R.; Tuomilehto-Wolf, E.; Tuomilehto, J.; Bingley, P.; Gillespie, K.M.; Undlien, D.E.; Ronningen, K.S.; Guja, C.; Ionescu-Tirgoviste, C.; Savage, D.A.; Maxwell, A.P.; Carson, D.J.; Patterson, C.C.; Franklyn, J.A.; Clayton, D.G.; Peterson, L.B.; Wicker, L.S.; Todd, J.A.; Gough, S.C. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423(6939), 506-511. (Pubitemid 36648570)
28. Saverino, D.; Brizzolara, R.; Simone, R.; Chiappori, A.; Milintenda-Floriani, F.; Pesce, G.; Bagnasco, M. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007, 123(2), 190-198.
29. Wong, C.K.; Lun, S.W.; Ko, F.W.; Ip, W.K.; Hui, D.S.; Lam, C.W. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 2005, 141(1), 122-129.
30. Anjos, S.; Nguyen, A.; Ounissi-Benkalha, H.; Tessier, M.C.; Polychronakos, C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002 277(48), 46478-46486.
31. Vaidya, B.; Oakes, E.J.; Imrie, H.; Dickinson, A.J.; Perros, P.; Kendall-Taylor, P.; Pearce, S.H. CTLA4 gene and Graves disease: association of Graves disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol (Oxf) 2003, 58(6), 732-735.
32. Hunt, K.A.; McGovern, D.P.; Kumar, P.J.; Ghosh, S.; Travis, S.P.; Walters, J.R.; Jewell, D.P.; Playford, R.J.; van Heel, D.A. A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet 2005, 13(4), 440-444.
33. Wang, X.B.; Pirskanen, R.; Giscombe, R.; Lefvert, A.K. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with humanmyasthenia gravis. J Intern Med 2008, 263(1), 61-69.
34. Atabani, S.F.; Thio, C.L.; Divanovic, S.; Trompette, A.; Belkaid, Y.; Thomas, D.L.; Karp, C.L. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol 2005, 35(7), 2157-2162.
35. Vanky, F.; Nagy, N.; Hising, C.; Sjovall, K.; Larson, B.; Klein, E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997, 43(6), 317-323.
36. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; Mc-Grady, G.;Wahl, S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198(12), 1875-1886.
37. Park, H.B.; Paik, D.J.; Jang, E.; Hong, S.; Youn, J. Acquisition of anergic and suppressive activities in transforming growth factorbeta- costimulated CD4+. Int Immunol 2004, 16(8), 1203-1213.